newsThe expanded authorisation of Reblozyl is based on a Phase…
4 April 2024 | By Catherine Eckford (European Pharmaceutical Review)
The expanded authorisation of Reblozyl is based on a Phase III trial which showed that the treatment nearly doubled the percentage of certain transfusion-dependent anaemia patients achieving haemoglobin increase, compared to epoetin alfa.